HRAS Mutation Cancer Clinical Trials

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

131 sites for NCT04284774

HRAS Mutation

Histiocytosis, +2 more conditions

tipifarnib

targeted therapy

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)

1 site for NCT05104567

HRAS Mutation, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +3 more conditions

cetuximab, +2 more drugs

immunotherapy, +1 more type

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

1 site for NCT04853043

APC Mutation, +4 more biomarkers

Colorectal Adenocarcinoma

cetuximab

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

4 sites for NCT05054374

ARAF Mutation, +18 more biomarkers

Breast Carcinoma, +1 more condition

fulvestrant, +1 more drug

hormone therapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab

3 sites for NCT05121038

BRAF Mutation, +3 more biomarkers

Appendix Adenocarcinoma, +2 more conditions

CEND-1, +2 more drugs

chemotherapy, +1 more type

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

2 sites for NCT04854434

HRAS Mutation, +2 more biomarkers

Colorectal Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +1 more type

Study of ASTX029 in Subjects With Advanced Solid Tumors

15 sites for NCT03520075

ARAF Mutation, +16 more biomarkers

Malignant Solid Tumor

ASTX029

targeted therapy

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma